About Us

The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Immunic CEO says Q2 results "couldn't be better"

--News Direct--

Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and a corporate update. Dr. Vitt says that the performance of the business during Q2 "couldn't have been better", highlighting what he calls "scientifically a very good quarter and uneventful on the more general financial side."

He goes on to give more detail about the progress achieved with Immunic's prospective multiple sclerosis (MS) and celiac disease treatments during the quarter, noting the preclinical data for its most advanced molecule IMU-838 that was published in the Journal of Medicinal Chemistry and positive results From Phase 1b Clinical Trial of IMU-856 in celiac disease. Looking to the future, Dr. Vitt expects more trial data to be released in the fall of this year, and reiterates that the company is fully funded into Q4 of 2024.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-ceo-says-q2-results-couldnt-be-better-574570986

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.